QT Imaging Q1 2024 EPS $(0.33) Down From $(0.20) YoY; Revenue $1.362M Up From $8,000
$QTI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
QT Imaging Q1 2024 EPS $(0.33) Down From $(0.20) YoY; Revenue $1.362M Up From $8,000
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that it will report financial results for the three and 12 months ended December 31, 2025 after market close on Wednesday, March 25, 2026 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Wednesday, March 25, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and uniqu
QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated configuration of its Breast Acoustic CT™ scanner, the Company's 3D ultrasound tomographic breast imaging system. The newly cleared enhanced configuration improves visualization and expands coverage of posterior breast tissue. "The updated configuration cleared by the FDA incorporates a tilted transmitter geometry that improves tomographic imaging coverage of breast tissue located near the che
QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that Mary W. Yamashita, MD will serve as Medical Advisor to the Company. In her role as QT Imaging Medical Advisor, Dr. Yamashita will provide strategic advisory and development support across several key areas, including clinical interpretation standards, structured reporting frameworks, training architecture, and reader study design. Her expertise will be instrumental in optimizing clinical integration and user experience, ensuring that the Company's technologies not only
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)
8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)
8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)
SCHEDULE 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)
Generated Scanner Sales Revenue of $1.4M with 56% Gross Margin in the First Quarter of 2024, Since the Company Became Public on March 4th Streamlined Business Model via Strategic Sales and Distribution Partnership in USA Reported in Academic Radiology the Results of a Second Blinded Screening Trial That Found That QTI Technology Is Similarly Effective as Digital Breast Tomosynthesis (DBT) or 3D Mammography Company Completed Merger with GigCapital5 QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the first qu
QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that it will report financial results for the three and 12 months ended December 31, 2025 after market close on Wednesday, March 25, 2026 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Wednesday, March 25, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and uniqu
Generated Record Revenue of $8.3 Million in Q4 2025, up 97% versus Q3 2025 Shipped Record 17 Scanners in Q4 2025 and 40 in 2025, up from 12 Scanners Shipped in 2024 Exceeded 2025 Sales Outlook, Delivering Revenue of $18.9 Million Relisted on Nasdaq Less Than One Year After Leaving the Exchange Continues to Pivot from a Scanner Company to a SaaS and Biomarker-Driven Medical Imaging Franchise QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company") a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announces preliminary unaudited financial results for the fourth quarter and full year
Generated Scanner Sales Revenue of $0.9 Million with 65% Gross Margin in the Third Quarter of 2024 The Company Successfully Completed the Engineering and Clinical Feasibility Study with its Strategic Partner The Company Announced Entering into Favorable Amendments to Its $10 Million Convertible Promissory Note with YA II PN, Ltd. The Company Announced Insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and their Affiliates QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results
SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)
SC 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)
SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)